IP disputes in focus as TPP talks resume

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

IP disputes in focus as TPP talks resume

Negotiators in Europe might still be preparing for the next round of transatlantic trade negotiations from the beach but those from countries on the Pacific Rim are already getting ready for a resumption in talks this week

Friday sees the start of the latest (the 19th in fact) round of talks for the Trans-Pacific Partnership (TPP) in Bandar Seri Begawan, Brunei. The country will play host to sherpas – the negotiators that do the heavy lifting before a deal is agreed – from the US, Australia, New Zealand, Chile, Peru, Brunei, Singapore, Malaysia, Vietnam, Canada, Mexico and Japan.

IP is already proving one of the hardest topics to resolve. That’s not surprising, given the gulf in economic development between, say, Vietnam on the one side and the US on the other.

TPP negotiators

The US government is understood to be pushing its trading partners to accept a range of so-called TRIPs-plus measures on IP, including patent term extensions and tougher rules on data exclusivity. It’s not just about pharmaceutical patents either. Negotiations continue to beef up regional rules on well-known trade marks, relax rules on what constitutes a trade mark and to give copyright owners more rights over their works.

So far, so what? The talks are simply rehashing old arguments about the level of protection countries should offer IP owners that have gone on since trade negotiators added IP to the table in the 1990s.

But what makes these talks different is the lengths to which negotiators are going to be seen to be open to all stakeholders. ACTA negotiators were stung (and ultimately beaten) by protestors angry about deals being conducted in secret and parliamentarians cross about being asked to rubber stamp agreements over which they had no control. Now many of the deal makers are trying to improve levels of transparency in the talks.

Of course some of this is window dressing. In the September issue of Managing IP we take a closer look at free trade deals and what they mean for IP owners and hear from stakeholders on both sides of the pharmaceutical patent divide. It still appears that big pharma has more direct access to their national negotiators than do groups that are sceptical about the expansion of IP rights.

But negotiators are providing more opportunities than ever for stakeholders to get involved. At the 16th round of TPP talks, for example, negotiations were adjourned for a day for meetings with some of the 300 stakeholders who were able to make it to Singapore. In Brunei a morning has been set aside for stakeholder presentations.

Such moves might not be enough to end complaints about secrecy and the close relationship between governments and big business. But they might help governments conclude an agreement that is more palatable to their electorates. As ACTA demonstrated, a one-sided deal can mean no deal at all.

more from across site and SHARED ros bottom lb

More from across our site

Licensing chief Patrik Hammarén also reveals that the company will rename its IPR business to better reflect its role in defining standards
The acquisition of Pecher & Partners follows the firm’s earlier expansion into litigation to create a ‘one-stop shop’
News of Via Licensing Alliance launching its first semiconductor patent pool and INTA electing a new president were also among the top talking points
Submit your nominations to this year's WIBL Americas Awards by January 23
The 2026 Life Sciences EMEA Awards is now open for entries. We are looking forward to reviewing and celebrating the industry's most impressive achievements and landmarks from the past year.
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
A dispute involving semiconductor technology and a partner's move from Hoffman Eitle to Hoyng Rokh Monegier were also among the top talking points
Gift this article